ClinConnect ClinConnect Logo
Search / Trial NCT06888258

Compare Analgesia Between MTP Block And ESPB in MRM

Launched by NATIONAL CANCER INSTITUTE, EGYPT · Mar 20, 2025

Trial Information

Current as of April 30, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is comparing two different methods of pain relief for patients undergoing modified radical mastectomy surgery, which is a type of surgery for breast cancer. The trial will look at the effectiveness of two techniques: one involves injecting medication near the spine (called the Erector Spinae Plane block), and the other involves a different injection method near the ribs (called the midpoint transverse process to pleura block). The goal is to see which method provides better pain control after surgery.

To be eligible for this trial, participants should be between the ages of 18 and 75, have a body mass index (BMI) between 18.5 and 30, and be classified as ASA I or II, which means they are generally healthy or have mild health issues. People who have certain medical conditions, are on blood thinners, or have allergies to local anesthetics cannot participate. Those who join the study can expect to receive one of the two pain relief methods during their surgery and will be monitored to see how well it works. This research is important because finding the best way to manage pain can help improve recovery for breast cancer patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ASA I-II.
  • Undergoing modified radical mastectomy surgery.
  • Body mass index (BMI) from 18.5 to 30 kg/m2
  • Exclusion Criteria:
  • Patient refusal.
  • Known allergy to local anesthetics.
  • Bleeding disorders; platelets count \<50,000 , prothrombin concentration \< 60% or any coagulopathy disorder.
  • Use of any anti-coagulants.
  • Inability to provide informed consent.
  • ASA III-IV.
  • Neurological disorders.
  • Patient with psychiatric disorders

About National Cancer Institute, Egypt

The National Cancer Institute, Egypt, is a premier research institution dedicated to advancing cancer prevention, treatment, and care through innovative clinical trials and comprehensive research initiatives. As a leading sponsor of clinical studies, the Institute focuses on understanding cancer biology, improving therapeutic strategies, and enhancing patient outcomes. With a commitment to scientific excellence and collaboration, the National Cancer Institute plays a crucial role in addressing the cancer burden in Egypt and the broader region, fostering partnerships with local and international researchers to drive forward the frontiers of oncology.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Trial Officials

Maie Kamal El-Din Helaly, MD

Study Director

National cancer institute, Cairo University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported